The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database

I am glad and proud to announce that a paper which I helped to prepare and publish is available on the Nature’s group site.

The paper, The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database, by Einat Gorelik et al. (including myself) analyzes the data in the FDA Adverse Event Reporting System (FAERS). In this study, we found interesting and relevant safety information about the long-term safety of the antiobesity drug Lorcaserin. Due to the interdisciplinary nature of the paper, the review process took about a year. Interestingly enough, the FDA requested the withdrawal of Lorcaserin due to long-term safety issues but not the ones we studied.

https://doi.org/10.1038/s41366-020-0544-4
https://doi.org/10.1038/s41366-020-0544-4

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s